MWA
VKTX icon

MN Wealth Advisors’s Viking Therapeutics VKTX Stock Holding History

MN Wealth Advisors’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.21M Sell
31,082
-450
-1% -$14.5K 0.52% 38
2026
Q1 		$1.03M Buy
31,532
+1,273
+4% +$40.9K 0.5% 43
2025
Q4 		$1.06M Buy
30,259
+3,262
+12% +$116K 0.54% 41
2025
Q3 		$709K Buy
26,997
+3,973
+17% +$119K 0.38% 57
2025
Q2 		$610K Buy
23,024
+4,396
+24% +$116K 0.36% 59
2025
Q1 		$450K Buy
18,628
+12,728
+216% +$402K 0.26% 69
2024
Q4 		$237K Buy
+5,900
New +$336K 0.13% 88

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

MN Wealth Advisors's VKTX Position: Q2 2026 in Review

MN Wealth Advisors reduced its Viking Therapeutics (VKTX) stake by 1.4% in Q2 2026, selling an estimated $14.5K and leaving 31,082 shares worth $1.21M. The position accounts for 0.52% of the portfolio, ranked #38.

MN Wealth Advisors first reported a position in VKTX in Q4 2024 and has held it in 7 quarters since. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • MN Wealth Advisors held 31,082 shares of Viking Therapeutics worth $1.21M as of Q2 2026.
  • MN Wealth Advisors sold 450 Viking Therapeutics shares in Q2 2026, an estimated $14.5K.
  • Viking Therapeutics made up 0.52% of MN Wealth Advisors's portfolio in Q2 2026, its #38 holding.
  • MN Wealth Advisors first reported a position in Viking Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on MN Wealth Advisors's 13F filing for Q2 2026, filed 23 Jul 2026.